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Background: Naltrexone has been proven to be an effective treatment option for the treatment of alcohol
dependency. In this article we introduce a reliable and simple method developed for the simultaneous
determination of naltrexone and 6-β-naltrexol in human serum by using high-performance liquid chromatography
(HPLC).
Findings: Liquid-liquid extraction with butyl acetate from basic solutions (pH 9) was chosen for extraction with
nalorphine as an internal standard (IS). Analytes were back-extracted from organic solvent into perchloric acid. The
acid extract was chromatographed by HPLC with a reverse-phase ODS-column and electrochemical detector. The
mobile phase was a NaH2PO4-solution with acetonitrile as an organic modifier and octanesulphonic acid and
tetraethylammonium hydrogen sulphate as ion-pair reagents. The recovery of the extraction method was 48% for
naltrexone and 75% for 6-β-naltrexol. The limit of quantification was 5.0 ng/ml for naltrexone and 1.0 ng/ml for
6-β-naltrexol. The analysed concentrations of naltrexone differed from the theoretic concentrations by 0.7 to 2.3%
and those of 6-β-naltrexol by 2.6%. The relative standard deviation of within-day assay was from 0.9 to 5.7% for
naltrexone and from 0.8 to 4.2% for 6-β-naltrexol; for the between-day assay it was 5.7% and 4.2%, respectively.
Conclusions: Our results indicate that the developed method is suitable for determination of naltrexone and
6-β-naltrexol in human serum.
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Naltrexone is an opioid receptor antagonist, which has
been used decades for the treatment of alcoholism [1-4]
and opiate dependency [5-7]. Several well-controlled
clinical trials have demonstrated that naltrexone is an
efficacious adjunctive medication in the treatment of al-
coholism [2,8,9]. Naltrexone has shown to reduce
relapse rates and alcohol craving among alcoholics as
compared to placebo-treated individuals [2]. Once admi-
nistered, naltrexone is known to undergo a rapid and ex-
tensive hepatic metabolism by enzymatic reduction from
ketone to a major metabolite 6-β-naltrexol (Figure 1)
and to other minor metabolites. 6-β-naltrexol is weaker* Correspondence: tuuli.lahti@thl.fi
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reproduction in any medium, provided the oropioid receptor antagonist than naltrexone, but it may
contribute to the clinical effects of the drug as it persists
in biological fluids in higher amounts than naltrexone
[10]. Naltrexone and its metabolites are mostly present
in conjugated forms [11-13]. Less reduction of naltrex-
one to 6-β-naltrexol seems to occur in liver cirrhosis,
and such alterations appear to be related to the severity
of liver disease [14,15].
Several methods for therapeutic drug monitoring of
naltrexone and 6-β-naltrexol have been developed over
the years. These include gas chromatography with electron
capture detection (GC-ECD) [13,16], high-performance li-
quid chromatography with electrochemical detection
(HPLC-EC) [17,18], gas chromatography–mass spectro-
metry (GC-MS) [19,20], and gas chromatography-tandem
mass spectrometry (GC-MS-MS) [21]. Recently Brünen
et al. [22] introduced two novel methods, HPLC/UV
(high-performance liquid chromatography and UVLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Metabolism of Naltrexone.
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chromatographic method coupled with tandem mass
spectrometry), for the determination of naltrexone and
6-β-naltrexol. The methods developed by Brünen et al. [22]
have several benefits, such as better automatization and
higher sensitivity, as compared to other methods developed
for the simultaneous quantitative determination of naltrex-
one and 6-β-naltrexol in biological fluids.
With therapeutic drug monitoring the treatment
outcomes of drugs can be significantly improved. It
has been suggested that therapeutic drug monitoring
should be a standard protocol while using naltrexone
for the treatment of substance abuse [23]. Thus weFigure 2 A chromatogram of a serum standard containing 50 ng/ml n
(RT = 5.13) as internal standard.aimed to develop even more efficient analysis method
for determi-nation of naltrexone and 6-β-naltrexol in
human serum than has been earlier developed. To
achieve this goal we used liquid-liquid extraction
and subsequent analysis by HPLC with electroche-
mical detection for determination of naltrexone and
6-β-naltrexol in human serum.
Materials and methods
The naltrexone (Dupont Merck) and 6-β-naltrexol
(NIDA) stock solutions were prepared in methanol to
give concentrations of 1 mg/ml of free base. These solu-
tions were used to prepare calibration curves coveringaltrexone (RT = 6.99) and 6-β- naltrexol (RT = 6.20), nalorphine
Figure 3 A chromatogram of a patient sample containing naltrexone (RT = 7.00) and 6-β-naltrexol (6.22), nalorphine as internal
standard (RT = 5.14).
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dards, blanks and quality control samples, were prepared
in drug-free cattle serum. All buffers were prepared with
deionized water.
Clinical sampling
Samples from 87 (23 women and 64 men) alcoholics
(DSM-IV) were taken. The alcoholics were participating
in a double blind, placebo-controlled, prospective
clinical trial evaluating naltrexone in the treatment of
alcohol dependence. The main inclusion criteria were:
age between 18–65, alcohol dependency (DSM-IV and
ICD-10). Naltrexone (naltrexone HCl, ReViaW) was
taken daily 50 mg orally every morning for a three-
month period. The blood sample was collected approxi-
mately 2–4 h after the medication consumption. Fasting
serum samples were collected by vein puncture at weeks
0, 2, and 8, and allowed to clot, and centrifuged (1000 g,
10 min, at room temperature). All samples were stored
at −70°C until analysis.
Extraction
1 ml of serum was extracted for all standard, quality con-
trol, and unknown clinical samples. The pH of the sample
was adjusted to pH 9 by 0.5 M Na2HPO4⋅2H2O. The
sample was extracted with 5 ml of butyl acetate with
nalorphine (1 μg / 100 ml) as the internal standard. AfterTable 1 The linearity range, mean correlation coefficient
(r2), and limit of quantification(LQ) with RSD-value for
naltrexone and 6-β-naltrexol
Compound Linearity range (ng/ml) r2 LQ (ng/ml) RSD (%)
Naltrexone 5-1000 0.9987 5 5.7
6-β-naltrexol 1-1000 0.992 1 15.4vortex-mixing (30 s), the sample was centrifuged, and the
upper butyl acetate layer was transferred to a clean test
tube and back-extracted into 150 μl of 0.1 M HClO4. After
vortex-mixing (30 s) and centrifugation, the upper butyl
acetate phase was thrown out. The acid phase was trans-
ferred to the autosampler vial, and 25 μl of the acid phase
was injected into the HPLC.
Chromatographic conditions
A Hewlett-Packard 1090 Series II high-performance
liquid chromatography with an Esa Coulochem 5100A
electrochemical coulometric detector (potentials: De-
tector 1 + 0.2 V, Detector 2 + 0.5 V) was used. The mobile
phase was acetonitrile-potassium dihydrogen phosphate
(19 mM) (10:45, v/v) with 1-octanesulphonic acid
(5 mM) and tetraethylammonium hydrogen sulphate
(5 mM) as ion-pair reagents. Chromatographic sepa-
ration was achieved using an ODS Hypersil reverse-
phase column (Hewlett Packard) with a length of
125 mm, an i.d. of 4 mm, and a particle size of 5 μm. The
mobile phase was pumped at a flow-rate of 1.2 ml/min.
The identification of drugs was based on retention
times, which were checked with calibration standards
before each run. An internal standard method with
linear one-point calibration based on peak heights was
used for quantification. Reliability of the method was
tested for linearity, accuracy, and within-day and
between-day assay precision. The suitability for deter-
mination of naltrexone and its major metabolite was
tested by analysing serum samples from patients partici-
pated in alcoholism treatment with naltrexone.
Results and discussion
Chromatograms of the control samples spiked with
naltrexone and 6-β-naltrexol and an unknown clinical
Table 2 Average concentrations found, accuracy and within-day assay precision for naltrexone and 6-β-naltrexol
Compound Concentration added (ng/ml) Concentration found (ng/ml) Accuracy (%) Precision (%)
Naltrexone 5 4.97 0.7 5.7
150 146.6 2.3 0.9
6-β-naltrexol 5 4.87 2.6 4.2
150 146.1 2.6 0.8
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retention times (min) of nalorphine (IS), 6-β-naltrexol,
and naltrexone were 5.1, 6.1, and 6.9, respectively. The
extraction recoveries at three concentration levels (100,
250, and 500 ng/ml) varied from 46.5 to 50.7% for
naltrexone and from 71.6 to 77.4% for 6-β-naltrexol.
Two sets of standard samples were prepared at a con-
centration range from 0 to 1000 ng/ml to determine the
linearity. The linearity ranges and the mean correlation
coefficients (r2) for naltrexone and 6-β-naltrexol are
shown in Table 1. The method was linear wide over the
concentration range of naltrexone and 6-β-naltrexol in
clinical samples.
The limit of quantification was determined by analys-
ing sets of six samples at low concentration levels. Rela-
tive standard deviations (RSD) of these samples were
calculated. Signal-to-noise ratio of at least three and
RSD-values below 20% were used as criteria for the limit
of quantification. The limits of quantification with RSD-
values for both compounds are shown in Table 1. The
accuracy and within-day precision of the assay was
tested at two concentration levels and with six samples.
The average of concentrations found, the accuracy, and
the within-day assay precision for naltrexone and
6-β-naltrexol are shown in Table 2.
Between-day precision of the assay was determined
by analysing the same serum standard 15 times in
30 days. A serum standard, spiked with 100 ng/ml of
naltrexone and 6-β-naltrexol, was stored at −20°C.
The average concentrations found were 98.8 and
98.9 ng/ml, and between-day assay precision was 5.7%
and 4.2% for naltrexone and 6-β-naltrexol, respect-
ively. Small changes in laboratory conditions (room
temperature, atmospheric moisture) had no effect on
the results. Retention times seemed to increase
slightly because of contamination within the chroma-
tographic system. This had, however, no effect on
results because the retention times were checked with
calibration standards before each determination. Al-
though the extraction recovery was relatively low, the
accuracy and the precision were good. The specific
stability validation was not performed, but the
between-day precision showed that the serum stand-
ard samples were stable for 30 days at −20°C. The
clinical serum samples were stored at −70°C.On the basis of validation results, the developed
method was found suitable for determination of naltrex-
one and 6-β-naltrexol in human serum. The within-day
and between-day assay precision was acceptable for all
tested concentration levels. The developed method was
used for determination of naltrexone and 6-β-naltrexol
in serum samples from patients participating in naltrex-
one treatment of alcoholism. Analysed serum samples
were collected after two and eight weeks of continuous
naltrexone treatment. Concentrations of naltrexone and
its major metabolite in serum samples varied greatly be-
tween patients. Naltrexone concentrations in serum
were 0–70 ng/ml after two weeks and 0–19 ng/ml
after eight weeks of continuous naltrexone treatment.
6-β-naltrexol concentrations were 15–136 ng/ml and
3–163 ng/ml after two and eight weeks, respectively.
6-β-naltrexol seemed to be the more reliable compound
to monitor because some unidentified compound was
found to interfere with the quantification of naltrexone.
The laboratory verification demonstrated the tests were
accurate in showing the levels of naltrexone and
naltrexol in serum samples, but high variability was seen
in the results from patients reporting that they were
taking naltrexone. The reasons for the variability in
practice remain to be determined but could have an in-
fluence on the efficacy of the treatment.
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